D Pratt1, N Tarrier2, G Dunn3, Y Awenat1, J Shaw4, F Ulph1, P Gooding1. 1. School of Psychological Sciences,University of Manchester,Manchester,UK. 2. Department of Psychology,Institute of Psychiatry,King's College London,London,UK. 3. Institute of Population Health,University of Manchester,Manchester,UK. 4. Institute of Brain,Behaviour and Mental Health,University of Manchester,Manchester,UK.
Abstract
BACKGROUND: Prisoners have an exceptional risk of suicide. Cognitive-behavioural therapy for suicidal behaviour has been shown to offer considerable potential, but has yet to be formally evaluated within prisons. This study investigated the feasibility of delivering and evaluating a novel, manualized cognitive-behavioural suicide prevention (CBSP) therapy for suicidal male prisoners. METHOD: A pilot randomized controlled trial of CBSP in addition to treatment as usual (CBSP; n = 31) compared with treatment as usual (TAU; n = 31) alone was conducted in a male prison in England. The primary outcome was self-injurious behaviour occurring within the past 6 months. Secondary outcomes were dimensions of suicidal ideation, psychiatric symptomatology, personality dysfunction and psychological determinants of suicide, including depression and hopelessness. The trial was prospectively registered (number ISRCTN59909209). RESULTS: Relative to TAU, participants receiving CBSP therapy achieved a significantly greater reduction in suicidal behaviours with a moderate treatment effect [Cohen's d = -0.72, 95% confidence interval -1.71 to 0.09; baseline mean TAU: 1.39 (S.D. = 3.28) v. CBSP: 1.06 (S.D. = 2.10), 6 months mean TAU: 1.48 (S.D. = 3.23) v. CBSP: 0.58 (S.D. = 1.52)]. Significant improvements were achieved on measures of psychiatric symptomatology and personality dysfunction. Improvements on psychological determinants of suicide were non-significant. More than half of the participants in the CBSP group achieved a clinically significant recovery by the end of therapy, compared with a quarter of the TAU group. CONCLUSIONS: The delivery and evaluation of CBSP therapy within a prison is feasible. CBSP therapy offers significant promise in the prevention of prison suicide and an adequately powered randomized controlled trial is warranted.
BACKGROUND: Prisoners have an exceptional risk of suicide. Cognitive-behavioural therapy for suicidal behaviour has been shown to offer considerable potential, but has yet to be formally evaluated within prisons. This study investigated the feasibility of delivering and evaluating a novel, manualized cognitive-behavioural suicide prevention (CBSP) therapy for suicidal male prisoners. METHOD: A pilot randomized controlled trial of CBSP in addition to treatment as usual (CBSP; n = 31) compared with treatment as usual (TAU; n = 31) alone was conducted in a male prison in England. The primary outcome was self-injurious behaviour occurring within the past 6 months. Secondary outcomes were dimensions of suicidal ideation, psychiatric symptomatology, personality dysfunction and psychological determinants of suicide, including depression and hopelessness. The trial was prospectively registered (number ISRCTN59909209). RESULTS: Relative to TAU, participants receiving CBSP therapy achieved a significantly greater reduction in suicidal behaviours with a moderate treatment effect [Cohen's d = -0.72, 95% confidence interval -1.71 to 0.09; baseline mean TAU: 1.39 (S.D. = 3.28) v. CBSP: 1.06 (S.D. = 2.10), 6 months mean TAU: 1.48 (S.D. = 3.23) v. CBSP: 0.58 (S.D. = 1.52)]. Significant improvements were achieved on measures of psychiatric symptomatology and personality dysfunction. Improvements on psychological determinants of suicide were non-significant. More than half of the participants in the CBSP group achieved a clinically significant recovery by the end of therapy, compared with a quarter of the TAU group. CONCLUSIONS: The delivery and evaluation of CBSP therapy within a prison is feasible. CBSP therapy offers significant promise in the prevention of prison suicide and an adequately powered randomized controlled trial is warranted.
Authors: Norbert Konrad; Marc S Daigle; Anasseril E Daniel; Greg E Dear; Patrick Frottier; Lindsay M Hayes; Ad Kerkhof; Alison Liebling; Marco Sarchiapone Journal: Crisis Date: 2007
Authors: Gregory K Brown; Thomas Ten Have; Gregg R Henriques; Sharon X Xie; Judd E Hollander; Aaron T Beck Journal: JAMA Date: 2005-08-03 Impact factor: 56.272
Authors: Paul Moran; Morven Leese; Tennyson Lee; Paul Walters; Graham Thornicroft; Anthony Mann Journal: Br J Psychiatry Date: 2003-09 Impact factor: 9.319
Authors: Lindsay A Bornheimer; Juliann Li Verdugo; Joshua Holzworth; Vitalis Im; Fonda N Smith; Hannah Sliwa; Stephan F Taylor; Cheryl A King; Timothy Florence; Nicholas Tarrier; Joseph A Himle Journal: Psychiatry Res Date: 2022-03-07 Impact factor: 11.225
Authors: Katrina G Witt; Sarah E Hetrick; Gowri Rajaram; Philip Hazell; Tatiana L Taylor Salisbury; Ellen Townsend; Keith Hawton Journal: Cochrane Database Syst Rev Date: 2021-04-22
Authors: Gillian Haddock; Linda Davies; Emma Evans; Richard Emsley; Patricia Gooding; Lisa Heaney; Sarah Jones; James Kelly; Ailsa Munro; Sarah Peters; Daniel Pratt; Nicholas Tarrier; Kirsten Windfuhr; Yvonne Awenat Journal: Trials Date: 2016-02-11 Impact factor: 2.279
Authors: Gillian Haddock; Daniel Pratt; Patricia A Gooding; Sarah Peters; Richard Emsley; Emma Evans; James Kelly; Charlotte Huggett; Ailsa Munro; Kamelia Harris; Linda Davies; Yvonne Awenat Journal: BJPsych Open Date: 2019-01